Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1991 1
1992 1
1994 1
1995 1
2009 1
2012 2
2013 5
2014 9
2015 7
2016 8
2017 6
2018 8
2019 4
2020 8
2021 10
2022 11
2023 8
2024 8
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

87 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation.
Ocio EM, Perrot A, Bories P, San-Miguel JF, Blau IW, Karlin L, Martinez-Lopez J, Wang SY, Bringhen S, Marcatti M, Mateos MV, Rodriguez-Otero P, Oliva S, Nogai A, Le Roux N, Dong L, Macé S, Gassiot M, Fitzmaurice T, Oprea C, Moreau P. Ocio EM, et al. Among authors: marcatti m. Leukemia. 2023 Jul;37(7):1521-1529. doi: 10.1038/s41375-023-01936-7. Epub 2023 Jun 14. Leukemia. 2023. PMID: 37316728 Free PMC article. Clinical Trial.
Advances in pharmacotherapy for cardiac amyloidosis.
Spoladore R, Falasconi G, Marcatti M, Di Maio S, Fiore G, Slavich M, Margonato A, Turco A, Fragasso G. Spoladore R, et al. Among authors: marcatti m. Expert Opin Pharmacother. 2021 Mar;22(4):469-481. doi: 10.1080/14656566.2020.1836159. Epub 2020 Oct 31. Expert Opin Pharmacother. 2021. PMID: 33043721 Review.
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients.
Morabito F, Martino EA, Galli M, Offidani M, Zambello R, Bringhen S, Giuliani N, Califano C, Brunori M, Gagliardi A, Sgherza N, Quinto AM, Barilà G, Belotti A, Cerchione C, Casaluci GM, Fontana R, Bongarzoni V, Tarantini G, Derudas D, Patriarca F, Gozzetti A, Sementa A, Antonioli E, Rago A, Lotti F, De Magistris C, Petrucci MT, Pettine L, Bolli N, Conticello C, Zamagni E, Palmieri S, Musso M, Mele A, Della Pepa R, Vigna E, Bruzzese A, Fazio F, Mina R, Paris L, Vincelli ID, Farina G, Cangialosi C, Mancuso K, Falcone AP, Mele G, Sica A, Morè S, Reddiconto G, Tripepi G, D'Arrigo G, Barbieri E, Quaresima M, Cartia CS, Pezzatti S, Marcatti M, Farina F, Cafro A, Palumbo M, Masoni V, Ferretti VV, Di Raimondo F, Musto P, Neri A, Mangiacavalli S, Gentile M. Morabito F, et al. Among authors: marcatti m. Eur J Haematol. 2025 Jul;115(1):16-28. doi: 10.1111/ejh.14413. Epub 2025 Mar 19. Eur J Haematol. 2025. PMID: 40103518 Free PMC article.
87 results